Overview

Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Status:
Active, not recruiting

Trial end date:
2021-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) administered via intratumoral injection as a single agent and in combination with ipilimumab.

Phase:

Phase 1

Details

Lead Sponsor:

Aduro Biotech, Inc.

Collaborator:

Novartis Pharmaceuticals

Treatments:

Ipilimumab